Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Phase 3 Terminated 460 enrolled Clearside Biomedical, Inc.

RandomizedParallel-groupTriple-blindTreatment

This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.

Evaluation	Drug	Modality	Dose	Route
Subject	CLS-TA	Unknown	4 mg	Other
Background	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal